Purple Biotech Ltd (PPBT) - Net Assets
Based on the latest financial reports, Purple Biotech Ltd (PPBT) has net assets worth ILA32.81 Million ILA (≈ $87.98K USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA39.06 Million ≈ $104.72K USD) and total liabilities (ILA6.25 Million ≈ $16.75K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Purple Biotech Ltd (PPBT) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA32.81 Million |
| % of Total Assets | 84.01% |
| Annual Growth Rate | 21.15% |
| 5-Year Change | -58.73% |
| 10-Year Change | N/A |
| Growth Volatility | 225.65 |
Purple Biotech Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Purple Biotech Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Purple Biotech Ltd for the complete picture of this company's asset base.
Annual Net Assets for Purple Biotech Ltd (2017–2024)
The table below shows the annual net assets of Purple Biotech Ltd from 2017 to 2024. For live valuation and market cap data, see market value of Purple Biotech Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA32.91 Million ≈ $88.23K |
-4.04% |
| 2023-12-31 | ILA34.30 Million ≈ $91.95K |
-27.18% |
| 2022-12-31 | ILA47.10 Million ≈ $126.27K |
-27.66% |
| 2021-12-31 | ILA65.11 Million ≈ $174.55K |
-18.36% |
| 2020-12-31 | ILA79.75 Million ≈ $213.81K |
+634.43% |
| 2019-12-31 | ILA10.86 Million ≈ $29.11K |
-1.32% |
| 2018-12-31 | ILA11.00 Million ≈ $29.50K |
+28.06% |
| 2017-12-31 | ILA8.59 Million ≈ $23.04K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Purple Biotech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10622100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA177.55 Million | 540.33% |
| Total Equity | ILA32.86 Million | 100.00% |
Purple Biotech Ltd Competitors by Market Cap
The table below lists competitors of Purple Biotech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PVW Resources Ltd
AU:PVW
|
$4.84 Million |
|
CARLSON INV. ZY 13
F:2HB
|
$4.84 Million |
|
Mecanica Sa Ce
RO:MECF
|
$4.85 Million |
|
Mittal Life Style Limited
NSE:MITTAL
|
$4.85 Million |
|
AquaBounty Technologies Inc
NASDAQ:AQB
|
$4.84 Million |
|
ArcWest Exploration Inc
V:AWX
|
$4.83 Million |
|
Eversafe Rubber Bhd
KLSE:0190
|
$4.83 Million |
|
Whitebark Energy Ltd
AU:WBE
|
$4.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Purple Biotech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,207,000 to 32,860,000, a change of -1,347,000 (-3.9%).
- Net loss of 7,240,000 reduced equity.
- New share issuances of 5,809,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-7.24 Million | -22.03% |
| Share Issuances | ILA5.81 Million | +17.68% |
| Other Changes | ILA84.00K | +0.26% |
| Total Change | ILA- | -3.94% |
Book Value vs Market Value Analysis
This analysis compares Purple Biotech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.53x to 15.74x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA0.65 | ILA1.00 | x |
| 2018-12-31 | ILA0.66 | ILA1.00 | x |
| 2019-12-31 | ILA0.53 | ILA1.00 | x |
| 2020-12-31 | ILA0.46 | ILA1.00 | x |
| 2021-12-31 | ILA0.37 | ILA1.00 | x |
| 2022-12-31 | ILA0.25 | ILA1.00 | x |
| 2023-12-31 | ILA0.14 | ILA1.00 | x |
| 2024-12-31 | ILA0.06 | ILA1.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Purple Biotech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-22.03%) is above the historical average (-57.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -167.81% | 0.00% | 0.00x | 1.94x | ILA-13.00 Million |
| 2018 | -49.42% | -520.00% | 0.07x | 1.40x | ILA-6.25 Million |
| 2019 | -56.14% | -585.00% | 0.07x | 1.41x | ILA-6.89 Million |
| 2020 | -35.27% | -2799.90% | 0.01x | 1.06x | ILA-35.94 Million |
| 2021 | -28.36% | 0.00% | 0.00x | 1.08x | ILA-24.87 Million |
| 2022 | -46.19% | 0.00% | 0.00x | 1.16x | ILA-26.36 Million |
| 2023 | -58.12% | 0.00% | 0.00x | 1.30x | ILA-23.30 Million |
| 2024 | -22.03% | 0.00% | 0.00x | 1.13x | ILA-10.53 Million |
Industry Comparison
This section compares Purple Biotech Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $104,302,885
- Average return on equity (ROE) among peers: -112.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Purple Biotech Ltd (PPBT) | ILA32.81 Million | -167.81% | 0.19x | $4.84 Million |
| BioLine RX Ltd (BLRX) | $31.77 Million | -32.03% | 0.14x | $9.10 Million |
| BioLight Life Sciences Ltd (BOLT) | $13.31 Million | 0.00% | 0.69x | $7.66 Million |
| Bonus Biogroup (BONS) | $84.43 Million | -106.69% | 0.24x | $123.99 Million |
| Can Fite Biopharma Ltd (CANF) | $2.44 Million | -516.99% | 2.35x | $5.56 Million |
| Clal Biotechnology Industries Ltd (CBI) | $808.20 Million | -3.45% | 0.28x | $12.61 Million |
| Compugen (CGEN) | $19.58 Million | -61.30% | 0.49x | $201.26 Million |
| DNA Biomed Solns (DNA) | $10.45 Million | 0.00% | 0.61x | $34.04 Million |
| Enlivex Therapeutics Ltd (ENLV) | $8.70 Million | -184.18% | 0.22x | $458.60K |
| Evogene (EVGN) | $56.88 Million | -46.07% | 0.26x | $4.88 Million |
| Kadimastem Ltd (KDST) | $7.28 Million | -173.39% | 0.71x | $22.18 Million |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more